Prostate Diseases

Reimbursement Support

Reimbursement Codes and Allowables

Reimbursement Guide

Patient Education

Prostate Diseases

Prostate Cancer

Benign Prostatic Hyperplasia (BPH)

Prostatitis

Helpful Links

Patient FAQs

Patient Information from Package Insert

Androgen Reduction Graph

Physician Information


	Bayer Global
	Bayer Corporate - USA

	general conditions of use privacy statement imprint © 2007 Bayer HealthCare Pharmaceuticals

Physician Support
Prostate Diseases

Viadur is indicated in the palliative treatment of advanced prostate cancer. Bayer is not responsible for, and does not endorse, any of the information found on these pages.

When men are first diagnosed with prostate disease, the first step in treatment is helping them understand what they have and what the treatment entails.

Find out more about prostate diseases and their treatment options by selecting a link below or at left.


		Prostate Cancer
		Benign Prostatic Hyperplasia (BPH)
		Prostatitis
		Helpful Links

When faced with a prostate cancer diagnosis, it is important to know that you and your family are not alone. In fact, prostate cancer is the most common type of cancer found in American men.¹ According to American Cancer Society estimates, 232,090 new cases of prostate cancer will be diagnosed in the United States in 2005.²

In order to begin to understand this disease, we need to begin with some basic background information about the prostate.

View Larger Image

The prostate is a relatively small, walnut-sized gland surrounding the urethra (see graphic at right) at the base of the urinary bladder in males.³ The main role of the gland is to add vital nutrients and fluid to the sperm.⁴ As the gland enlarges from normal growth or from cancer, it may cause narrowing of the urinary passage making it difficult to urinate.⁵

The three most common types of prostate disease are benign prostate hyperplasia (BPH), prostatitis, and prostate cancer.⁶


		Benign prostatic hyperplasia (BPH)
		Prostatitis
		Prostate cancer

Viadur is indicated in the palliative treatment of advanced prostate cancer and not for benign prostatic hyperplasia or prostatitis.

Printer-Friendly Version

References


	Important Safety Considerations Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression. The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).
	Distributed and Marketed by:	Manufactured by:
	Bayer HealthCare Pharmaceuticals 6 West Belt, Wayne, NJ 07470 USA
	© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation. The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.